The main drug, Cipla, said on Monday that it received final approval from the American Health Regulator for tablets Valganciclovir, which is used to treat viral Eye Virus in patients with AIDS.
Valganciclovir tablets are used in the infection of the cytomegalovirus infection (severe infection of the virus in the eyes of the retina) in patients with AIDS and in the prevention of cytomegalovirus (CMV) after organ transplantation.
Approved products are generic therapeutic equivalent versions of Roche's Valcite. Cipla has approved a 450 mg product from the US Food and Drug Administration (USFDA), the company said in a BSE submissions.
Citing the IKVIA (IMS Health) data, Cipla said that Valcite and its generic equivalents had sales in the US of about $ 79 million for a 12 month period ending in September 2018.